These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9526146)

  • 1. Parkinsonian patients report blunted subjective effects of methylphenidate.
    Persico AM; Reich S; Henningfield JE; Kuhar MJ; Uhl GR
    Exp Clin Psychopharmacol; 1998 Feb; 6(1):54-63. PubMed ID: 9526146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.
    Cantello R; Aguggia M; Gilli M; Delsedime M; Chiardò Cutin I; Riccio A; Mutani R
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):724-31. PubMed ID: 2664088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain reward system activity in major depression and comorbid nicotine dependence.
    Cardenas L; Tremblay LK; Naranjo CA; Herrmann N; Zack M; Busto UE
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1265-71. PubMed ID: 12183688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate.
    Linssen AM; Vuurman EF; Sambeth A; Nave S; Spooren W; Vargas G; Santarelli L; Riedel WJ
    Psychopharmacology (Berl); 2011 Dec; 218(3):533-42. PubMed ID: 21597989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers.
    Bernard K; Penelaud PF; Mocaër E; Donazzolo Y
    J Clin Psychopharmacol; 2011 Aug; 31(4):441-8. PubMed ID: 21694627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal response to methylphenidate across multiple fMRI procedures in cocaine use disorder: feasibility study.
    Moeller SJ; Konova AB; Tomasi D; Parvaz MA; Goldstein RZ
    Psychopharmacology (Berl); 2016 Jul; 233(13):2559-69. PubMed ID: 27150080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile exposure to methylphenidate reduces cocaine reward and alters netrin-1 receptor expression in adulthood.
    Argento JK; Arvanitogiannis A; Flores C
    Behav Brain Res; 2012 Apr; 229(1):202-7. PubMed ID: 22249134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.
    Alburges ME; Hoonakker AJ; Horner KA; Fleckenstein AE; Hanson GR
    J Neurochem; 2011 May; 117(3):470-8. PubMed ID: 21323925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease.
    Evans AH; Lawrence AD; Lees AJ
    J Neurol Neurosurg Psychiatry; 2009 Mar; 80(3):267-72. PubMed ID: 18977820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate significantly alters the functional coupling between the prefrontal cortex and dopamine neurons in the ventral tegmental area.
    Dela Peña IC; Shen G; Shi WX
    Neuropharmacology; 2018 Mar; 131():431-439. PubMed ID: 29339293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment.
    Roache JD; Grabowski J; Schmitz JM; Creson DL; Rhoades HM
    J Clin Psychopharmacol; 2000 Feb; 20(1):61-8. PubMed ID: 10653210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease.
    van der Vegt JP; Hulme OJ; Zittel S; Madsen KH; Weiss MM; Buhmann C; Bloem BR; Münchau A; Siebner HR
    Brain; 2013 Apr; 136(Pt 4):1192-203. PubMed ID: 23442226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
    Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
    Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects.
    Volkow ND; Wang GJ; Ma Y; Fowler JS; Wong C; Jayne M; Telang F; Swanson JM
    Neuroimage; 2006 Oct; 32(4):1782-92. PubMed ID: 16757181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate restores ventral tegmental area dopamine neuron activity in prenatal ethanol-exposed rats by augmenting dopamine neurotransmission.
    Choong KC; Shen RY
    J Pharmacol Exp Ther; 2004 May; 309(2):444-51. PubMed ID: 14724217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic modulation of brain systems subserving decision making under uncertainty: a study with fMRI and methylphenidate challenge.
    Schlösser RG; Nenadic I; Wagner G; Zysset S; Koch K; Sauer H
    Synapse; 2009 May; 63(5):429-42. PubMed ID: 19184997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensory-evoked potentials recordings from the ventral tegmental area, nucleus accumbens, prefrontal cortex, and caudate nucleus and locomotor activity are modulated in dose-response characteristics by methylphenidate.
    Yang PB; Swann AC; Dafny N
    Brain Res; 2006 Feb; 1073-1074():164-74. PubMed ID: 16473326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha(2C)-Adrenoceptors modulate the effect of methylphenidate on response rate and discrimination accuracy in an operant test.
    Ihalainen JA; Tanila H; Scheinin M; Riekkinen P
    Brain Res Bull; 2001 Mar; 54(5):553-7. PubMed ID: 11397547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.